Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fever

Coding Corner Question: Medical Chart Review of an Infliximab Infusion

From the College  |  June 21, 2018

A 73-year-old female established patient with rheuma­toid arthritis affecting multiple joints and with positive rheumatoid factor returns to the office for an infliximab infusion. She denies any fevers, cough, dyspnea or concurrent illness. She has joint pain of 6 on the pain scale. She is on an NSAID, weekly methotrexate subcutaneous injections, folic acid and…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & Codinginfliximab

Pediatric Rheumatologist Dr. Lynn Punaro Loves a Good Mystery

Kelly Tyrrell  |  May 18, 2018

When Marilynn “Lynn” Punaro, MD, MACR, isn’t working with medical students, seeing patients in the clinic, participating in translational research or performing leadership duties, she’s enjoying a good book—especially a good mystery. This shouldn’t be a surprise. It was mystery that led Dr. Punaro to a career in pediatric rheumatology more than 30 years ago,…

Filed under:Profiles Tagged with:Association of Rheumatology Professionals (ARP)Dr. Lynn Punaro

The Diagnostic View: Assess Your Rheumatology Knowledge

The Diagnostic View: Assess Your Rheumatology Knowledge

Sunita Paudyal, MD, & Laura B. Herpel, MD  |  May 17, 2018

Editor’s note: In this occasional feature, we first present a series of images (this page) for your review, and then a brief discussion of the findings and diagnosis. Before you read the discussion, examine these images carefully and draw your own conclusions. History A 39-year-old white woman with a three-year history of seropositive rheumatoid arthritis…

Filed under:Conditions Tagged with:pulmonary nodulespulmonary nodulosisTNF inhibitors

FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine

Michele B. Kaufman, PharmD, BCGP  |  May 8, 2018

The FDA Arthritis Advisory Committee has recommended the approval of 2 mg baricitinib (but not in a 4 mg dose) for treating adults with moderate to severe active RA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:baricitinibFood and Drug Administrationhemophagocytic lymphohistiocytosisHLHlamotrigineU.S. Food and Drug Administration (FDA)

Clinical Remission Should Be Target of JIA Treatment: Task Force

Reuters Staff  |  April 27, 2018

NEW YORK (Reuters Health)—An international task force says patients with juvenile idiopathic arthritis (JIA) should be treated to a target of clinical remission, among other new recommendations. “The Task Force is convinced that transferring (the recommendations) into clinical practice will significantly improve the outcomes in patients with JIA,” Dr. Angelo Ravelli of the Istituto G….

Filed under:ConditionsPractice SupportProfessional Topics Tagged with:Angelo Ravelliclinical remissioninternational task forcejuvenile idiopathic arthritis (JIA)

Experts Discuss Proposed Giant Cell Arteritis Risk Tool

Kathy Holliman  |  April 26, 2018

A proposed model to predict the risk of giant cell arteritis (GCA) prior to a temporal artery biopsy could help triage patients and guide decision making about the need for biopsy or monitoring (see Figure 1). There’s no specific biomarker for GCA, and GCA can be a “diagnostic conundrum, especially when it presents in an…

Filed under:Vasculitis Tagged with:Giant Cell ArteritisVasculitis

Kussmaul, Meier & Polyarteritis Nodosa

Ruth Jessen Hickman, MD  |  April 26, 2018

In 1866, Adolf Kussmaul, an internist, and Rudolf Maier, a pathologist, published the classic characterization of what eventually became known as polyarteritis nodosa.1 It was the first scientific clinical characterization of a noninfectious vasculitis. As such, it became a paradigmatic point of contrast to other types of vasculitides that were later described. Their description also…

Filed under:Vasculitis Tagged with:HistoryLost & Foundpolyarteritis nodosascientific methodVasculitis

Rheumatology Coding Corner Question: RA Follow-Up with Imaging

From the College  |  April 26, 2018

History A 39-year-old woman returns for follow-up for her rheumatoid arthritis. She has positive rheumatoid factor, but no organ or systemic involvement. She has joint swelling and pain in her left hand, right elbow and right knee. Her pain is at an 8 on a 10-point scale. She states the pain is worse in the…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & CodingRheumatoid arthritis

Chikungunya Arthritis

Arthritis & Rheumatology  |  March 28, 2018

In this review, the authors address the key pathophysiologic mechanisms that drive acute and chronic chikungunya arthritis, arguably the most incapacitating sequela among long-lasting chikungunya virus disease manifestations, based on recent animal experimental disease models and epidemiologic studies. They explore the latest findings in therapeutic development aimed at limiting viral spread and at immune and…

Filed under:Conditions Tagged with:Arthritischikungunyacontracted chikungunya virus

Rheumatology Coding Corner Question: Follow-Up Knee Injection

From the College  |  March 19, 2018

On Nov. 4, a 55-year-old female patient presents to the office for a follow-up visit for injection of the left knee for osteoarthritis. This is her third of three injections that were preauthorized through Oct. 31. She reports pain and swelling in her left knee and rates the pain at an 8 on a 10-point…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & CodingKnee Osteoarthritis (OA)preauthorizationprior authorization

  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 54
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences